REPL - Replimune Group Inc

-

$undefined

N/A

(N/A)

Replimune Group Inc NasdaqGS:REPL Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Location: 500 Unicorn Park Drive, Woburn, MA, 01801, United States | Website: https://www.replimune.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

144.1M

Cash

536.5M

Avg Qtr Burn

-46.17M

Short % of Float

17.29%

Insider Ownership

4.61%

Institutional Own.

-

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

PDUFA

Approval decision

RP2 + Opdivo Details
Cancer, Uveal melanoma

Phase 2/3

Data readout

RP1 + Opdivo Details
Cancer, Non-melanoma skin cancer

Phase 2

Update

RP1 + Libtayo (cemiplimab) Details
Cutaneous squamous cell carcinoma, Cancer

Phase 2

Update

Phase 2

Initiation

RP1 Details
Cancer, Cutaneous squamous cell carcinoma, Kidney transplantation, Liver transplant, Skin cancer

Phase 1/2

Data readout

RP2 +/- Opdivo Details
Solid tumor/s, Cancer, Breast cancer, Head and neck cancer, Lung cancer, Hepatocellular carcinoma

Phase 1

Update

(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details
Cancer, Colorectal cancer , Hepatocellular carcinoma

Failed

Discontinued

RP3 +/- Opdivo Details
Solid tumor/s, Cancer, Lung cancer, Breast cancer, Head and neck cancer

Failed

Discontinued

RP3 in comb w/std. of care Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued